Skip to main
NEO
NEO logo

NeoGenomics (NEO) Stock Forecast & Price Target

NeoGenomics (NEO) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 22%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

NeoGenomics Inc. demonstrates a positive financial outlook, evidenced by an adjusted gross margin of 46.8%, which reflects a year-over-year increase of 150 basis points, and an adjusted EBITDA margin of 4.2%, up 200 basis points, surpassing consensus expectations. Additionally, revenue per test increased by 2.7% to $459 in the fourth quarter of 2024, supported by improvements in pricing, revenue cycle management (RCM), and a favorable mix of next-generation sequencing (NGS) testing. Furthermore, NGS testing revenue surged by 18% in the first quarter of 2025, highlighting significant growth in a crucial segment of its service offerings.

Bears say

NeoGenomics Inc. faces significant headwinds due to disappointing non-clinical sales, which totaled $18.3 million, falling short of the consensus estimate of $20.9 million and representing a 15.6% decline compared to previous growth rates. The company is also exposed to potential risks including negative reimbursement changes, patent litigation challenges, and increased competition, which could further erode market share. Additionally, greater than expected reinvestment demands may result in weaker EBITDA margins, compounding the challenges faced by the company in its current financial landscape.

NeoGenomics (NEO) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 22% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeoGenomics (NEO) Forecast

Analysts have given NeoGenomics (NEO) a Buy based on their latest research and market trends.

According to 9 analysts, NeoGenomics (NEO) has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeoGenomics (NEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.